Argenx is urging patients to “Live Vyvidly.” The biotech put the message out in a direct-to-consumer TV ad that paints ...

Although CIDP can cause significant impairment, it is treatable, and as many as 40% of people reach a state of cure or remission with effective therapies. As an immune-mediated condition ...

After a run-in period, during which people who were taking other medicines for CIDP stopped treatment for up to 12 weeks, everyone in the study used Vyvgart Hytrulo once per week for 12 weeks ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) diagnoses are frequently missed or delayed and standard treatments - ...

In a statement, Argenx said that the subcutaneously administered drug is the first “meaningful” new treatment option for the approximately 24,000 people living with CIDP in the US in more than ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...